

**Notice Pursuant to the National Cooperative Research and Production Act of 1993—Durability and Life Assessment of GTD-111 Buckets**

Notice is hereby given that, on October 31, 1995, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* ("the Act"), Southwest Research Institute ("SwRI") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing (1) the identities of the parties and (2) the nature and objectives of the venture. The notifications were filed for the purpose of invoking the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Pursuant to Section 6(b) of the Act, the identities of the parties are ARCO Alaska, Inc., Anchorage, AK; Exxon Research and Engineering Company, Florham Park, NJ; and, Mobil Exploration & Producing Technical Center, a unit of Mobil Research & Development Corporation, Dallas, TX. The general areas of planned activities are to develop the necessary technology to assess the life of coated gas turbine buckets made from GTD-111 as used in the General Electric line of gas turbines by defining and quantifying the rate of the actual degradation; by developing the properties of these buckets; by developing a life assessment methodology and software program to determine the conditions of the buckets; and by developing nondestructive evaluation (NDE) methods for assessing the coatings. The focus of the program is on the model MS5002 gas turbine.

Membership in the program remains open, and SwRI intends to file additional written notifications

disclosing all changes in the membership or planned activities.

Constance K. Robinson,  
Director of Operations, Antitrust Division.  
[FR Doc. 96-26605 Filed 10-16-96; 8:45 am]  
BILLING CODE 4410-01-M

**Drug Enforcement Administration**

[DEA #153P]

**Controlled Substances: Proposed Aggregate Production Quotas for 1997**

**AGENCY:** Drug Enforcement Administration (DEA), Justice.

**ACTION:** Notice of proposed aggregate production quotas for 1997.

**SUMMARY:** This notice proposes initial 1997 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act. **DATES:** Comments or objections should be received on or before November 18, 1996.

**ADDRESSES:** Send comments or objections to the Administrator, Drug Enforcement Administration, Washington, D.C. 20537, Attn: DEA Federal Register Representative (CCR).

**FOR FURTHER INFORMATION CONTACT:** Frank L. Sapienza, Chief, Drug & Chemical Evaluation Section, Drug Enforcement Administration, Washington, D.C. 20537; Telephone: (202) 307-7183.

**SUPPLEMENTARY INFORMATION:** Section 306 of the Controlled Substances Act (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations. The Administrator, in turn, has redelegated this function to the Deputy Administrator of the DEA pursuant to Section 0.104 of Title 28 of the Code of Federal Regulations.

The quotas are to provide adequate supplies of each substance for: (1) the estimated medical, scientific, research, and industrial needs of the United States; (2) lawful export requirements; and (3) the establishment and maintenance of reserve stocks.

In determining the below listed proposed 1997 aggregate production quotas, the Deputy Administrator considered the following factors: (1) total actual 1995 and estimated 1996 and 1997 net disposals of each substance by all manufacturers; (2) estimates of 1996 year end inventories of each substance and of any substance manufactured from it and trends in accumulation of such inventories; (3) product development requirements of both bulk and finished dosage form manufacturers; (4) projected demand as indicated by procurement quota applications filed pursuant to Section 1303.12 of Title 21 of the Code of Federal Regulations and (5) other pertinent information.

Pursuant to Section 1303.23(c) of Title 21 of the Code of Federal Regulations, the Deputy Administrator of the DEA will, in early 1997, adjust aggregate production quotas and individual manufacturing quotas allocated for the year based upon 1996 year-end inventory and actual 1996 disposition data supplied by quota recipients for each basic class of Schedule I or II controlled substance.

Therefore, under the authority vested in the Attorney General by Section 306 of the Controlled Substances Act of 1970 (21 U.S.C. 826), delegated to the Administrator of the DEA by Section 0.100 of Title 28 of the Code of Federal Regulations, and redelegated to the Deputy Administrator by Section 0.104 of Title 28 of the Code of Federal Regulations, the Deputy Administrator hereby proposes that the aggregate production quotas for 1997 for the following controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class	Proposed 1997 quotas
Schedule I:	
2,5-Dimethoxyamphetamine .....	15,200,100
2,5-Dimethoxy-4-ethylamphetamine (DOET) .....	2
3-Methylfentanyl .....	14
3-Methylthiofentanyl .....	2
3,4-Methylenedioxyamphetamine (MDA) .....	22
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .....	27
3,4-Methylenedioxymethamphetamine (MDMA) .....	7
3,4,5-Trimethoxyamphetamine .....	2
4-Bromo-2,5-Dimethoxyamphetamine .....	2
4-Bromo-2,5-Dimethoxyphenethylamine (2-CB) .....	2
4-Methoxyamphetamine .....	17
4-Methylaminorex .....	2
4-Methyl-2,5-Dimethoxyamphetamine (DOM) .....	2

Basic class	Proposed 1997 quotas
5-Methoxy-3,4-Methylenedioxyamphetamine .....	2
Acetyl-alpha-methylfentanyl .....	2
Acetylmethadol .....	7
Alpha-acetylmethadol .....	7
Alpha-ethyltryptamine .....	2
Alpha-methadol .....	2
Alpha-methylfentanyl .....	2
Alpha-methylthiofentanyl .....	2
Aminorex .....	7
Beta-acetylmethadol .....	2
Beta-hydroxyfentanyl .....	2
Beta-hydroxy-3-methylfentanyl .....	2
Beta-methadol .....	2
Bufotenine .....	2
Cathinone .....	9
Codenine-N-oxide .....	2
Difenoxin .....	14,000
Dihydromorphine .....	7
Ethylamine Analog of PCP .....	5
Heroin .....	2
Lysergic acid diethylamide (LSD) .....	27
Mescaline .....	7
Methaqualone .....	17
Methcathinone .....	11
Morphine-N-oxide .....	2
N-Ethylamphetamine .....	7
N-Hydroxy-3,4-Methylenedioxyamphetamine .....	2
N,N-Dimethyltryptamine .....	7
Norlevorphanol .....	2
Normethadone .....	7
Normorphine .....	7
Para-fluorofentanyl .....	2
Pholcodine .....	2
Psilocin .....	2
Psilocybin .....	2
Tetrahydrocannabinols .....	25,100
Thiofentanyl .....	2
Thiophene Analog of Phencyclidine .....	5
Schedule II:	
1-Phenylcyclohexylamine .....	10
1-Piperidinocyclohexanecarbonitrile (PCC) .....	12
Alfentanil .....	9,300
Amobarbital .....	15
Amphetamine .....	2,968,000
Carfentanil .....	500
Cocaine .....	550,100
Codeine (for sale) .....	49,103,000
Codeine (for conversion) .....	19,679,000
Desoxyephedrine .....	1,422,000
1,361,000 grams of levodesoxyephedrine for use in a noncontrolled, nonprescription product and 61,000 grams for methamphetamine.	
Dextropropoxyphene .....	116,469,000
Dihydrocodeine .....	255,100
Diphenoxylate .....	701,000
Ecgonine (for conversion) .....	651,000
Ethylmorphine .....	12
Fentanyl .....	137,000
Glutethimide .....	2
Hydrocodone (for sale) .....	13,891,000
Hydrocodone (for conversion) .....	1,769,000
Hydromorphone .....	563,000
Isomethadone .....	12
Levo-alpha-acetylmethadol (LAAM) .....	200,100
Levomethorphan .....	2
Levorphanol .....	16,400
Meperidine .....	9,843,000
Methadone (for sale) .....	3,729,000
Methadone (for conversion) .....	364,000
Methadone Intermediate (for conversion) .....	4,295,000
Methamphetamine (for conversion) .....	723,000
Methylphenidate .....	13,824,000
Morphine (for sale) .....	11,126,000

Basic class	Proposed 1997 quotas
Morphine (for conversion) .....	68,165,000
Noroxymorphone (for conversion) .....	2,000,000
Opium .....	937,000
Oxycodone (for sale) .....	5,589,000
Oxycodone (for conversion) .....	1,200
Oxymorphone .....	9,000
Pentobarbital .....	16,772,000
Phencyclidine .....	60
Phenmetrazine .....	2
Phenylacetone .....	10
Secobarbital .....	491,000
Sufentanil .....	1,000
Thebaine .....	9,325,000

The Deputy Administrator further proposes that aggregate production quotas for all other Schedules I and II controlled substances included in Sections 1308.11 and 1308.12 of Title 21 of the Code of Federal Regulations be established at zero.

All interested persons are invited to submit their comments and objections in writing regarding this proposal. A person may object to or comment on the proposal relating to any of the above-mentioned substances without filing comments or objections regarding the others. If a person believes that one or more of these issues warrant a hearing, the individual should so state and summarize the reasons for this belief.

In the event that comments or objections to this proposal raise one or more issues which the Deputy Administrator finds warrant a hearing, the Deputy Administrator shall order a public hearing by notice in the Federal Register, summarizing the issues to be heard and setting the time for the hearing.

The Office of Management and Budget has determined that notices of aggregate production quotas are not subject to centralized review under Executive Order 12866. This action has been analyzed in accordance with the principles and criteria contained in Executive Order 12612, and it has been determined that this matter does not have sufficient federalism implications to warrant the preparation of a Federalism Assessment.

The Deputy Administrator hereby certifies that this action will have no significant impact upon small entities whose interests must be considered under the Regulatory Flexibility Act, 5 U.S.C. 601, et seq. The establishment of annual aggregate production quotas for Schedules I and II controlled substances is mandated by law and by international treaty obligations. While aggregate production quotas are of primary importance to large manufacturers, their impact upon small entities is neither

negative nor beneficial. Accordingly, the Deputy Administrator has determined that this action does not require a regulatory flexibility analysis.

Dated: October 10, 1996.

James S. Milford,

*Acting Deputy Administrator.*

[FR Doc. 96-26581 Filed 10-16-96; 8:45 am]

BILLING CODE 4410-09-M

## DEPARTMENT OF LABOR

### Pension and Welfare Benefits Administration

[Application No. D-10150, et al.]

#### Proposed Exemptions; Smith Barney Shearson Prototype

**AGENCY:** Pension and Welfare Benefits Administration, Labor.

**ACTION:** Notice of Proposed Exemptions.

**SUMMARY:** This document contains notices of pendency before the Department of Labor (the Department) of proposed exemptions from certain of the prohibited transaction restriction of the Employee Retirement Income Security Act of 1974 (the Act) and/or the Internal Revenue Code of 1986 (the Code).

#### *Written Comments and Hearing Requests*

All interested persons are invited to submit written comments or request for a hearing on the pending exemptions, unless otherwise stated in the Notice of Proposed Exemption, within 45 days from the date of publication of this Federal Register Notice. Comments and request for a hearing should state: (1) The name, address, and telephone number of the person making the comment or request, and (2) the nature of the person's interest in the exemption and the manner in which the person would be adversely affected by the exemption. A request for a hearing must also state the issues to be addressed and

include a general description of the evidence to be presented at the hearing. A request for a hearing must also state the issues to be addressed and include a general description of the evidence to be presented at the hearing.

**ADDRESSES:** All written comments and request for a hearing (at least three copies) should be sent to the Pension and Welfare Benefits Administration, Office of Exemption Determinations, Room N-5649, U.S. Department of Labor, 200 Constitution Avenue, N.W., Washington, D.C. 20210. Attention: Application No. stated in each Notice of Proposed Exemption. The applications for exemption and the comments received will be available for public inspection in the Public Documents Room of Pension and Welfare Benefits Administration, U.S. Department of Labor, Room N-5507, 200 Constitution Avenue, N.W., Washington, D.C. 20210.

#### *Notice to Interested Persons*

Notice of the proposed exemptions will be provided to all interested persons in the manner agreed upon by the applicant and the Department within 15 days of the date of publication in the Federal Register. Such notice shall include a copy of the notice of proposed exemption as published in the Federal Register and shall inform interested persons of their right to comment and to request a hearing (where appropriate).

**SUPPLEMENTARY INFORMATION:** The proposed exemptions were requested in applications filed pursuant to section 408(a) of the Act and/or section 4975(c)(2) of the Code, and in accordance with procedures set forth in 29 CFR Part 2570, Subpart B (55 FR 32836, 32847, August 10, 1990). Effective December 31, 1978, section 102 of Reorganization Plan No. 4 of 1978 (43 FR 47713, October 17, 1978) transferred the authority of the Secretary of the Treasury to issue exemptions of the type requested to the Secretary of